Takkavatakarn, Kullaya
Oh, Wonsuk
Cheng, Ella
Nadkarni, Girish N
Chan, Lili
Funding for this research was provided by:
National Institutes of Health (T32DK007757, R01DK108803, U01HG007278, U01HG009610, U01DK116100, K23DK124645)
Article History
Received: 4 October 2023
Accepted: 5 December 2023
First Online: 19 December 2023
Declarations
:
: GNN is a founder of Renalytix, Pensieve, Verici and provides consultancy services to AstraZeneca, Reata, Renalytix, Siemens Healthineer and Variant Bio, serves a scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, Pensieve and Verici. LC is a consultant for Vifor Pharma INC and has received honorarium from Fresenius Medical Care. All remaining authors have declared no conflicts of interest.
: .
: The study was performed in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study was approved by the Mount Sinai Institutional Review Board (STUDY-20-00338) which allowed for analysis of patient-level data with a waiver of informed consent.
: Not Applicable.